Cell and Gene Therapy Market Size, Share & Industry Analysis by Type (Cell Therapy {Therapy Type [CAR-T Cell Therapy, TCR-T Cell Therapy, Natural Killer (NK) Cells, and Others], Product Type [Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Others], Indication [Oncology and Others]} and Gene Therapy {Product Type [Zolgensma, Luxturna, Roctavian, and Others], Vector Type [Viral Vectors and Non-Viral Vectors], Indication [Genetic Disorders, Ophthalmology, Hematology, and Others]}), By End User (Hospitals & Clinics, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI114130

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2025-2032
Historical Period	2019-2023
Growth Rate	CAGR of 35.09% from 2025-2032
Unit	Value (USD Billion)
Segmentation	By Type Cell Therapy Therapy Type CAR-T Cell Therapy TCR-T Cell Therapy Natural Killer (NK) Cells Others Product Type Kymriah Yescarta Tecartus Breyanzi Abecma Carvykti Others Indication Oncology Others Gene Therapy Product Type Zolgensma Luxturna Roctavian Others Vector Type Viral Vectors Non-Viral Vectors Indication Genetic Disorders Ophthalmology Hematology Others By End User Hospitals & Clinics Specialty Clinics Others By Geography North America (By Type, End User, and Country) U.S. Canada Europe (By Type, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Type, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Type, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Type, End User, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa